Deloitte XPRIZE to serve as a catalyst for change in cancer | Deloitte US has been added to your bookmarks.
Look again. New ways to fight cancer.
From early detection to treatment and cures
Cancer care is changing fast. Breakthroughs in treatments, payment and commercial models, research and development, regulation, and much more are all rapidly evolving. We at Deloitte are involved in this transformation and committed to leveraging our capabilities, experience, and ecosystems to innovate and collaborate to find a cure for cancer. We are focused on applying innovative technologies and analytics as mechanisms to improve the quality of oncology care.
- Watch the video
- Ready for launch
- The evolution of oncology payment models
- Commercializing curative therapies
- Top 10 health care innovations
- How we are helping clients with oncology challenges
- In the news
- Learn more
- Get in touch
- Join the conversation
- Related topics
Fighting cancer through early detection: Deloitte XPRIZE to serve as a catalyst for change in cancer
Deloitte Cancer XPRIZE certified by XPRIZE as “ready for launch”
Saving millions of lives globally from cancer is one step closer to a reality as Deloitte’s Cancer XPRIZE, co-led by Deloitte health leaders and pediatric oncologist Dr. Daniel Kraft, is now officially “ready for launch.” XPRIZE convened nine international teams to share their impact design proposals across a portfolio of grand challenge areas at the Visioneers 2016 Summit. Now, Deloitte is working with XPRIZE to create a scientific advisory
About the XPRIZE
Teams will develop a means to accurately, rapidly, and
Accurately: A solution must be sensitive to detect cancer early enough for effective intervention, yet specific to avoid over-diagnosis.
Rapidly: Reducing or eliminating the time between a test being conducted and the delivery of its results is key to addressing disparities in cancer screening.
Affordably: Significantly reducing the cost of cancer screening is key to making it more available.
Perspectives from our leaders:
- Targeted cancer therapies are the next frontier of treatment, but room to innovate and improve chemotherapy in the meantime
- Improving patient outcomes through changes to oncology payments
- As World Cancer Day approaches, how are patient-centered solutions transforming breakthroughs in oncology and beyond?
The evolution of oncology payment models: What can we learn from early experiments?
Pioneering health plans and provider groups are experimenting with value-based payment models in oncology to try to improve the cost-effectiveness of cancer care. They are piloting these models in the commercial market—financial incentives for adhering to clinical pathways, patient-centered medical homes (PCMHs), bundled payments, and accountable care organizations—and it is uncertain which will achieve the dual goals of improving outcomes and controlling costs.
We interviewed health plans and providers participating in emerging payment models to review early results (financial and clinical), understand which approaches are working, and discuss considerations for these models’ future evolution.
Commercializing curative therapies: Challenges and implications for biopharmaceutical companies
Advances in the understanding of disease biology combined with the development of new treatment modalities, including gene and cell therapy, are paving the way for a paradigm shift—from managing a disease to curing it. However, developing and manufacturing cures and treatments for complex diseases can be a daunting and costly process.
Companies ushering potentially curative treatments to market will need to navigate an outdated reimbursement model and a distinct set of challenges related to pricing and market access, biopharma resourcing models, and (for complex treatments) the health care delivery system and manufacturing/supply chain.
Top 10 health care innovations: More value, better outcomes, for less
Health care is an industry in need of innovation. Health plans, providers, life sciences companies, and the government are facing rising costs and inconsistent outcomes. They are working to improve care and health outcomes, all while reducing costs and spending. What innovations are most likely to help stakeholders achieve these goals and transform health care over the next 10 years?
How we are helping clients with oncology challenges
To help cure cancer,
These connections can provide the glue needed to build a network—an ecosystem—of collaborators who can re-architect cancer research and discovery in a holistic manner.
In the news:
Nine teams propose XPRIZE competitions to address grand challenges at Visioneers Summit
All teams result in viable future XPRIZE concepts, with top three teams certified as “ready for launch” in the areas of cancer, avatars, and ALS.
The Cancer Moonshot initiative: Taking a giant leap toward a cure
Dr. Terri Cooper, Federal Health leader, discusses her experience at the Cancer Moonshot Summit in this issue of Health Care Current.
Deloitte’s response to Vice President’s Cancer Moonshot
In response to the Cancer Moonshot call to action, Deloitte is designing an XPRIZE in cancer.
White House Fact Sheet announcing Deloitte’s Cancer Moonshot XPRIZE
Deloitte Consulting LLP is working alongside players across the cancer ecosystem, from governments to non-profit advocacy groups, and from R&D to health care delivery, to facilitate the development and improvement of cancer diagnosis, treatment, and care.
- Federal Health Care Sector Services
- Solving the country’s opioid crisis
- Public Population Health Services
- Blockchain: Opportunities for health care
- Delivering data and technology solutions to Federal Health entities
You may also like